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Abstract 
A sofosbuvir/ledipasvir combination is part of a first-line treatment of hepatitis C. However, 
in patients concurrently treated with amiodarone, cardiac side effects have been described, 
resulting in an official warning in 2015 by the American Food and Drug Administration and 
the European Medicines Agency when combining those substances. This deprived numerous 
hepatitis C patients with concurrent cardiovascular problems of receiving this highly effective 
treatment. Here we present a treatment alternative with an elbasvir/grazoprevir regimen, 
based on our successful treatment of a patient under concurrent amiodarone therapy. Our 
observations indicate that patients treated with amiodarone can finally benefit from effective 
antiviral therapy. © 2018 The Author(s) 
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Introduction 
A sofosbuvir/ledipasvir combination is part of a first-line treatment of hepatitis C with a 
sustained virological response of around 99% [1]. However, in patients concurrently treated 
with amiodarone, bradyarrhythmias and scarcely other arrhythmic disorders have been 
described [2, 3], resulting in an official warning in 2015 by the American Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) when combining those 
substances [4, 5]. Until now, patients in whom amiodarone therapy is essential and cannot 
be discontinued could not benefit from an effective antiviral therapy. Here we present a first 
case of successful antiviral treatment with elbasvir/grazoprevir under concurrent amioda-
rone therapy in a patient who had previously shown drug interactions between sofosbuvir/ 
ledipasvir and amiodarone. 
Case Report 
The patient, who was a 52-year-old male of Mongolian origin, had cyanotic congenital 
heart disease. He was born with a large ventricular septal defect that was not repaired in 
childhood. Over the years, he developed severe shunt-induced pulmonary hypertension 
leading to shunt reversal (Eisenmenger syndrome) with a resting oxygen saturation of 85–
90%. He was in functional NYHA class II–III and suffered from recurrent sustained supra-
ventricular tachycardia. Therefore, he was under continuous treatment with amiodarone 
200 mg/day, metoprolol 75 mg/day, and sildenafil 60 mg/day. From a clinical point of view 
the patient’s cardiovascular symptoms were well controlled with the given medication. Be-
ing dependent on both medication and regular medical checkups, he was able to work and 
lead a more or less normal life. 
His further medical record consisted of a chronic hepatitis C (genotype 1B), primary bil-
iary cholangiopathy, condition after hepatitis B and tuberculosis, hypothyroidism, and 
chronic kidney disease (see Table 1 for an overview). He first presented to our Hepatology 
Outpatient Clinic in 2013. 
For his chronic hepatitis C he had been treated twice elsewhere with pegylated interfer-
on and ribavirin in 2003 and 2006, but had shown viral relapse both of these times. In De-
cember 2015, we intended to treat the patient with a combination of sofosbuvir 400 mg and 
ledipasvir 60 mg (Harvoni®). Since the FDA Drug Safety Communication and the EMA had 
warned about serious bradycardia when amiodarone was combined with sofosbuvir-
containing drugs like Harvoni®, we wanted the patient to stop amiodarone before and dur-
ing antiviral therapy. Before the patient was seen by a cardiologist to decide whether amio-
darone could be stopped or switched to an alternative drug, the patient took a dose of Har-
voni® accidentally at home while still taking amiodarone. He developed symptomatic brady-
cardia with a heart rate of 30 bpm. An emergency physician applied 50 µg fentanyl and 1 mg 
midazolam i.v. and started external provisional pacing. The patient was then admitted to our 
emergency department by air rescue. At admission, his resting ECG showed sinus arrest. 
With isoprenaline i.v., he developed a frequency-dependent AV block type II and remained 
with a bradycardic heart rate. Finally, a temporary pacemaker wire had to be placed in the 
atrium, despite his markedly increased risk for paradoxical systemic embolism as an Eisen-
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menger patient. After 1 day his condition improved and the majority of heartbeats were self-
triggered, resulting in a frequency of 61 bpm. Two days after hospitalization the temporary 
pacemaker was removed and the patient was discharged in a stable condition. 
Because of the language barrier, the patient’s complex heart disease that definitely re-
quired continuous amiodarone treatment, and his presentation of highly dangerous drug 
interactions, we decided against further treatment attempts with an antiviral therapy con-
taining sofosbuvir. Due to a lack of treatment alternatives at that time, we saw him for regu-
lar follow-ups to monitor his liver function, FibroScan, and viral activity. 
In 2016, a new class of antiviral drugs was approved in Switzerland, amongst others 
Zepatier® (MSD Merck Sharp & Dohme AG), a combination of elbasvir, an NS5A inhibitor, 
and grazoprevir, an NS3/4A protease inhibitor, for oral treatment of chronic hepatitis C vi-
rus (HCV) genotypes 1 and 4 [6]. 
In the end of 2016, the patient presented with progressive liver disease graded Child  
A6, MELD 13, demonstrated by elevated liver enzymes (Fig. 1a; Table 2), a FibroScan of  
16.5 kPa, CAP 300 dB/m, and an ultrasound showing progressive fibrotic changes in the 
liver. We conducted a liver biopsy that revealed steatotic and fibrotic parenchyma graded 
METAVIR A2F3, SAF score S2 A2 F3, the latter score confirming nonalcoholic steatohepatitis. 
The patient complained about being increasingly tired and about intermittent pain in the 
upper right quadrant of his abdomen resulting in recurrent sick days and inability to partake 
in everyday life. Considering these progressive findings and his augmented hepatological 
risk profile due to his primary biliary cholangiopathy, manifesting with positive AMA-M2 
antibodies (1:1,280), and nonalcoholic steatohepatitis shown in his ultrasound and biopsy, 
we were urged to reconsider antiviral therapy. Because of his other comorbidities, foremost 
his kidney disease and hypothyroidism, we decided for a treatment attempt with elbasvir/ 
grazoprevir. Due to the patient’s history of cardiac complications under antiviral treatment, 
we hospitalized him for 2 days in February of 2017 to introduce the medication under tele-
metric control while he continued using amiodarone. The surveillance and therapy introduc-
tion worked without any incident, demonstrated by stable ECG results, so that the patient 
was discharged after 2 days. 
During the 12-week therapeutic period we did regular follow-ups every 2–3 weeks in 
close collaboration with the cardiologists. Apart from palpitations uttered by the patient, 
which were without any ECG correlate, the patient showed an improving general state. He 
reported being less tired and a decrease in the above-mentioned abdominal pain. Palpita-
tions are described as frequent side effects of Zepatier® by the producer [7], therefore we 
regarded them as such. 
Liver enzymes started to normalize as early as 2 weeks after the beginning of the elbas-
vir/grazoprevir treatment (Fig. 1a; Table 2). The hepatitis C viremia decreased over the first 
few weeks, with an undetectable virus content 1 month after therapy induction (Fig. 1c; Ta-
ble 2). During the first few weeks the patient’s kidney values increased but returned to a 
stable level towards the end of therapy (Fig. 1b; Table 2). 
With a sustained virological response 12 weeks after the end of antiviral treatment with 
elbasvir/grazoprevir, our patient was considered cured of his hepatitis C. With regard to the 
comorbidities and the complicated history including two viral relapses following interferon 
therapy and cardiac complications under sofosbuvir, we consider this a big success. 
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Discussion 
The literature gives multiple examples of drug interactions between amiodarone and 
sofosbuvir-containing drugs like Harvoni® or Sovaldi®, with bradyarrhythmias and scarcely 
other cardiac arrhythmic disorders sometimes even leading to serious life-threatening com-
plications [2, 3]. Due to recommendations of the FDA and the EMA following these reports 
not to combine amiodarone with sofosbuvir-containing antiviral treatment regimens [4, 5], 
many multimorbid patients with cardiac comorbidities accompanying their chronic HCV 
infection were deprived of a highly effective HCV therapy. Our patient, who was treated with 
an elbasvir/grazoprevir antiviral regimen while concurrently taking amiodarone, is to our 
knowledge the first published case of a successful antiviral hepatitis C treatment alternative 
in comedication with amiodarone. Since drug interactions are hard to anticipate and not 
nearly every individual under concurrent amiodarone and sofosbuvir therapy will necessari-
ly develop complications, our treatment strategy needed to be effective in a patient who had 
previously shown drug interactions. In our case, this was further complicated by social fac-
tors such as a massive language barrier and cultural differences as well as numerous comor-
bidities. This underlines the necessity for social awareness, an individualized treatment ap-
proach, and impeccable planning. 
Our antiviral therapy approach with elbasvir/grazoprevir under concurrent amioda-
rone treatment presents a new perspective of successfully treating this group of often high-
risk patients. However, in order to avoid serious interactions between drugs as previously 
seen under sofosbuvir, treatment introduction under telemetric control for the first couple 
of days is advised until further data for those specific cases are available. 
Although no cases of pharmacological interactions with amiodarone for elbasvir/grazo-
previr are known and the described interactions between sofosbuvir and amiodarone are 
most likely caused by a direct cardiotoxic effect of sofosbuvir rather than enzyme interac-
tions [8], a potential risk due to a slight CYP3A4 inhibition by grazoprevir does exist [7, 9]. 
Grazoprevir in return can be affected by strong CYP3A4 inhibitors [7], and although amioda-
rone is known to only cause a slight CYP3A4 inhibition, drug interactions are often difficult 
to anticipate, especially in multimorbid patients [8]. 
Although widely successful, hepatitis C therapy is still a challenge, especially in patients 
with multiple comorbidities. Therefore, special care and attention should be paid to drug 
interactions and individualized treatment strategies. 
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Fig. 1. Overview of the laboratory results at the time of the patient’s initial presentation in 2013, the results 
at the end of 2016 leading to the treatment decision with elbasvir/grazoprevir, during, at the end, and  
12 weeks after (SVR 12) elbasvir/grazoprevir treatment. a Overview and development of liver values.  
b Overview and development of kidney values. c Overview and development of hepatitis C viremia. 
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Table 1. Characteristics of the patient 
  
  
Age, years 52 
    Sex male 
    Origin Mongolian 
    HCV genotype 1B 
    Child/MELD A6/13 
    Secondary diagnoses nonrestrictive ventricular septal defect, NYHA II–III, Eisenmenger  
syndrome; recurrent episodes of AVNRT and AVTR; hypothyroidism;  
condition after hepatitis A and B; primary biliary cholangiopathy;  
nonalcoholic steatohepatitis; chronic kidney disease KDIGO 2 
    Medication amiodarone (200 mg/day); sildenafil (60 mg/day); metoprolol 
(12.5 mg/day); torasemide (5 mg/day); allopurinol (100 mg/day);  
levothyroxine (125 µg/day); ferric hydroxide (100 mg/day);  
ursodeoxycholic acid (900 mg/day) 
    Antiviral medication 2015: one dose of sofosbuvir 400 mg and ledipasvir 60 mg (Harvoni®);  
2017: 12-week therapy with elbasvir 50 mg and grazoprevir 100 mg  
(Zepatier®), SVR 12 
    Adverse events under  
sofosbuvir/ledipasvir 
sinus arrest and AV block type II, bradycardia of 30 bpm; temporary  
pacemaker for 3 days; 3-day hospitalization 
    Adverse events under  
elbasvir/grazoprevir 
episodes of palpitations without pathological ECG correlation 
  
  
HCV, hepatitis C virus. 
  
  
 
 
Table 2. Overview of the patient’s laboratory results at different time points 
         
         
 Initial  
presentation  
3 months before  
elbasvir/grazoprevir 
2 weeks of  
treatment  
4 weeks of  
treatment  
6 weeks of  
treatment  
9 weeks of  
treatment  
End of  
therapy  
SVR 12  
         
         
Liver values         
ALT, U/L 033 124 027 023 026 020 024 019 
AST, U/L 049 128 032 035 035 033 035 032 
Gamma-GT, U/L 123 252 117 085 071 053 045 039 
AP, U/L 068 086 082 081 082 073 091 073 
                  Kidney values         
Creatinine, µmol/L 102 101 136 122 101 115 123 106 
eGFR, mL/min 073 073 051 058 072 062 057 068 
                  Viremia         
Quantit. RNA-PCR, IU/mL 3,612,790 381,378 016 negative <15 negative  negative  negative  
         
         
 
 
 
